This disclosure relates to hydrogel compositions with isolated mitochondria suspended therein. The compositions are for providing protection to injured tissue, as well as tissue proximal to a site of injury. The hydrogel provides structural support while the mitochondria are able to prevent or slow cellular death. In some aspects, the compositions include N-acetylcysteine amide and/or acetyl-L-carnitine.

This disclosure relates to hydrogel compositions with isolated mitochondria suspended therein. The compositions are for providing protection to injured tissue, as well as tissue proximal to a site of injury. The hydrogel provides structural support while the mitochondria are able to prevent or slow cellular death. In some aspects, the compositions include N-acetylcysteine amide and/or acetyl-L-carnitine.

The present disclosure relates to novel lymphoid-specific tyrosine phosphatase (LYP, encoded by the PTPN22 gene) inhibitors, and to methods of making and using the novel LYP inhibitors. Thus, the compounds according to the disclosure may be used for treating diseases or disorders associated with PTPN22 genetic polymorphism, including type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosis, Graves' disease, Addison's disease, vitiligo, juvenile arthritis, Hashimoto thyroiditis, and other rarer diseases. Furthermore, these LYP inhibitors may be served for a novel class of cancer immunotherapy. The compounds can be injected or orally administered.

The present invention provides methods and compositions for treating synaptic dysfunction and spinal cord injuries comprising, for example, the administration of a compound that increases the level of PZP in vivo.

The present invention provides methods and compositions for treating synaptic dysfunction and spinal cord injuries comprising, for example, the administration of a compound that increases the level of PZP in vivo.

The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.

The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.

The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.

Disclosed herein are compositions and methods for treating a subject having cancer and other ferroptosis disorders with high density lipoprotein-like nanoparticles that induce ferroptosis.

Disclosed herein are compositions and methods for treating a subject having cancer and other ferroptosis disorders with high density lipoprotein-like nanoparticles that induce ferroptosis.